Bhat Laxminarayan Amends Reviva Pharma Holdings

TL;DR

**Major shareholder Bhat Laxminarayan just updated his Reviva Pharma stake, watch for market reaction!**

AI Summary

Bhat Laxminarayan filed an amended Schedule 13D/A on February 16, 2024, regarding his holdings in Reviva Pharmaceuticals Holdings, Inc. The filing indicates a change in beneficial ownership, specifically related to the Common Stock, par value $0.0001 per share, of the issuer. The event triggering this amendment occurred on November 20, 2023, and the filing was authorized by Steven M. Skolnick, Esq. of Lowenstein Sandler LLP.

Why It Matters

This amendment provides updated information on a significant shareholder's stake, which can influence investor perception and potentially the company's stock performance.

Risk Assessment

Risk Level: low — This is an amendment to a previous filing, indicating a change in beneficial ownership rather than a new, potentially disruptive event.

Key Players & Entities

• Bhat Laxminarayan (person) — Filing Person
• Reviva Pharmaceuticals Holdings, Inc. (company) — Issuer
• Steven M. Skolnick, Esq. (person) — Authorized to Receive Notices
• Lowenstein Sandler LLP (company) — Legal Counsel
• $0.0001 (dollar_amount) — Par value per share

FAQ

Key Financial Figures

• $0.0001 — ame of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securitie

Filing Documents

• bhat20240216_sc13da.htm (SC 13D/A) — 37KB
• 0001437749-24-004592.txt ( ) — 38KB

SECURITY AND ISSUER

ITEM 1. SECURITY AND ISSUER

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 1 of the Schedule 13D is hereby amended and restated in its entirety as follows: The securities to which this Schedule 13D relates are shares of Common Stock of the Issuer, whose principal executive offices are located at 10080 N Wolfe Road, Suite SW3-200, Cupertino, California 95014.

IDENTITY AND BACKGROUND

ITEM 2. IDENTITY AND BACKGROUND

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 2 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a) Name: Laxminarayan Bhat (b) Business Residence: 10080 N Wolfe Road, Suite SW3-200, Cupertino, California 95014 (c) Present Occupation: The Reporting Person is the President, Chief Executive Officer and a Director of the Issuer. (d) During the last five years, the Reporting Person has not been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors). (e) During the past five years, the Reporting Person has not been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction and as a result of such proceeding was or is subject to a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws. (f) Citizenship: United States

INTEREST IN SECURITIES OF THE ISSUER

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.

of the Schedule 13D is hereby amended and restated in its entirety as follows

Item 5 of the Schedule 13D is hereby amended and restated in its entirety as follows: (a-b) As of November 20, 2023 (the "Event Date"), for purposes of Rule 13d-3 promulgated under the Securities and Exchange Act of 1934, as amended (the "Act"), the Reporting Person was the beneficial owner of 2,860,967 shares of Common Stock, which represented approximately 10.1% of the outstanding shares of Common Stock, based on 27,918,560 shares of Common Stock outstanding as of November 20, 2023, as reported directly by the Issuer to the Reporting Person. Of the 2,860,967 shares of Common Stock beneficially owned by the Reporting Person as of the Event Date, for purposes of Rule 13d-3 under the Act, the Reporting Person: (A) had sole voting power and dispositive power with respect to an aggregate of 2,755,733 of such shares, consisting of (i) 2,478,856 shares of Common Stock held by the Reporting Person, and (ii) 276,877 shares of Common Stock issuable upon the exercise of options held by the Reporting Person that were exercisable or would have been exercisable within 60 days of the Event Date; and (B) may be deemed to share voting power and dispositive power with respect to an aggregate of 105,234 of such shares, consisting of (i) 5,388 shares of Common Stock held by the Reporting Person's spouse, and (ii) 99,846 shares of Common Stock issuable upon the exercise of options held by the Reporting Person's spouse that were exercisable or would have been exercisable within 60 days of the Event Date. As of the filing date of this Amendment (the "Filing Date"), for purposes of Rule 13d-3 promulgated under the Act, the Reporting Person is the beneficial owner of an aggregate of 2,885,678 shares of Common Stock, which represents approximately 10.2% of the outstanding shares of Common Stock, based on 27,918,560 shares of Common Stock outstanding as of February 16, 2024, as reported directly by the Issuer to the Reporting Person. Of the 2,885,678 shares of Common Stock reported as be